2-(1,8-Naphthyridin-3-yl)quinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(1,8-Naphthyridin-3-yl)quinoxaline
• 英文别名: 2-(1,8-naphthyridin-3-yl)quinoxaline
• 化学式: C₁₆H₁₀N₄
• 分子量: 258.28
• InChiKey: AFJRUTDQZCOWGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US10246442B2

  公开（公告）日：2019-04-02

  Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.

  描述了式 (I) 的氨基喹唑啉化合物、 可用作脯氨酰羟化酶抑制剂。此类化合物可用于治疗由脯氨酰羟化酶活性介导的疾病状态、紊乱和病症的药物组合物和方法中。因此，这些化合物可用于治疗贫血、血管疾病、代谢紊乱和伤口愈合等。
• Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
  申请人：UCB Biopharma SRL

  公开号：US10889584B2

  公开（公告）日：2021-01-12

  The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

  本发明涉及某些式（I）的双环双杂环芳基化合物、含有它们的药物组合物以及使用它们的方法，包括预防、逆转、减缓或抑制蛋白质聚集的方法，以及治疗与蛋白质聚集有关的疾病的方法、包括神经退行性疾病，如帕金森病、阿尔茨海默病、路易体病、帕金森病伴痴呆症、额颞叶痴呆症、亨廷顿氏病、肌萎缩性脊髓侧索硬化症和多系统萎缩，以及癌症，包括黑色素瘤。
• Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
  申请人：UCB Biopharma SRL

  公开号：US11091474B2

  公开（公告）日：2021-08-17

  The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

  本发明涉及某些双杂环芳基化合物、含有它们的药物组合物以及使用它们的方法，包括预防、逆转、减缓或抑制蛋白质聚集的方法，以及治疗与蛋白质聚集有关的疾病的方法、包括神经退行性疾病，如帕金森病、阿尔茨海默病、路易体病、帕金森病伴痴呆症、前颞叶痴呆症、亨廷顿氏病、肌萎缩性脊髓侧索硬化症和多系统萎缩，以及癌症，包括黑色素瘤。
• SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS
  申请人：University of Notre Dame du Lac

  公开号：US20170015647A1

  公开（公告）日：2017-01-19

  The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.
• 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20170320859A1

  公开（公告）日：2017-11-09

  Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.